Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)

Journal of the American College of Cardiology

Volumn 35, Issue 1, 2000, Pages 60-66

  Anderson, Todd J ^a,d   Elstein, Eleanor ^b   Haber, Harry ^c   Charbonneau, François ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c PFIZER INC   (United States)

^d FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN; CALCIUM CHANNEL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLYCERYL TRINITRATE; LOSARTAN; QUINAPRIL;

ADULT; ARTICLE; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VASODILATATION;

AGED; AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD FLOW VELOCITY; CALCIUM CHANNEL BLOCKERS; CORONARY CIRCULATION; CORONARY DISEASE; DRUG THERAPY, COMBINATION; ENALAPRIL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; ISOQUINOLINES; LOSARTAN; MALE; MIDDLE AGED; TETRAHYDROISOQUINOLINES; VASODILATION;

EID: 0033966627     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00537-9     Document Type: Article

References (43)

1. Pfeffer MA. ACE inhibition in acute myocardial infarction. N Engl J Med 1995;332:118-20.
2. Dzau VJ, Burt DW, Pratt RE. Molecular biology to the reninangiotensin system. Am J Physiology 1988;255:F563-F573.
3. Moncada S, Higgs A. The 1-arginine-NO pathway. N Engl J Med 1993;329:2002-12.
4. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
5. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-7.
6. Vanhoutte PM, Boulanger CM, Illiano SC, Nagao T, Vidai M, Mombouli J-V. Endothelium-dependent effects of converting-enzyme inhibitors. J Cardiovasc Pharmacol 1993;22:S10-S16.
7. Cachofeiro V, Sakakibara T, Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension 1992;19:138-45.
8. Sudhir K, Chou TM, Hutchison SJ, Chatterjee SJ. Coronary vasodilation induced by angiotensin-converting enzyme inhibition in vivo: differential contribution of nitric oxide and bradykinin in conductance and resistance arteries. Circulation 1996;93:1734-9.
9. Sudhir K, MacGregor JS, Gupta M, et al. Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo: intravascular twodimensional and doppler ultrasound studies. Circulation 1993;87: 931-8.
10. Janiak P, Libert O, Vilaine JP. Role of the renin-angiotensin system in neointima formation after injury in rabbits. Hypertension 1994;24: 671-8.
11. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND study. Circulation 1996;94:258-65.
12. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: An unexpected mechanism of action of a calcium-blocking agent. Circulation 1998;97:576-80.
13. Anderson TJ, Uehata A, Gerhard MD, et al. Close relationship of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235-41.
14. Sorensen KE, Celermajer DS, Spiegelhalter DJ, et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995;74:247-53.
15. Leadon SA, Cerutti PA. A rapid and mild procedure for the isolation of DNA from mammalian cells. Anal Biochem 1982;120:282-8.
16. Rigat B, Hubert C, Corvol P. PCR detection of the insertion/deletion plymorphism of the human angiotensin converting enzyme gene (DCP-1). Nucl Acids Res 1992;20:1433.
17. Senn S. Cross-over trials in clinical research. New York: John Wiley and Sons; 1993.
18. Schiffrin EL, Deng LY, Larochelle P. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in arterial hypertension. Hypertension 1994;23:83-91.
19. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular Superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
20. Finta KM, Fischer MJ, Lee L, Gordon D, Pitt B, Webb RC. Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis 1993;100:149-56.
21. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115-8.
22. Berkenboom G, Langer I, Carpentier Y, Grosfils K, Fontaine J. Ramipril prevents endothelial dysfunction induced by oxidized lowdensity lipoproteins: A bradykinin-dependent mechanism. Hypertension 1997;30:371-6.
23. Johnson CI, Fabris B, Yamada H, et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 1989;7:S11-S16.
24. Fabris B, Jackson B, Cubela R, Mendelsohn FA, Johnson CI. Angiotensin converting enzyme in the rat heart; studies of its inhibition in vitro and ex vitro. Clin Exp Pharmacol Physiol 1989;16:309-13.
25. Lyons D, Webster J, Benjamin N. Effect of enalapril and quinapril on forearm vascular ACE in man. Eur J Clin Pharmacol 1997;51:373-8.
26. Hornig B, Arakawa N, Haussmann D, Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;98: 2842-8.
27. O'Driscoll G, Green D, Rankin J, Stanton K, Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997;100:678-84.
28. Mullen MJ, Clarkson P, Donald AE, et al. Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: a randomized, double-blind study. J Am Coll Cardiol 1998;31:1330-5.
29. Winkelmann BR, Nauck M, Klein B, et al. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease [see comments]. Ann Intern Med 1996;125:19-25.
30. Haberbosch W, Bohle RM, Franke FE, et al. The expression of angiotensin-I converting enzyme in human atherosclerotic plaques is not related to the deletion/insertion polymorphism but to the risk of restenosis after coronary interventions. Atherosclerosis 1997;130:203-13.
31. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sorensen TI, Jensen G, Tybjaerg-Hansen A. ACE gene polymorphism: ischemic heart disease and longevity in 10,150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation 1997;95:2358-67.
32. Mizuiri S, Hemmi H, Inoue A, et al. Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism. Nephron 1997;75:310-4.
33. Celermajer DS, Sorensen KE, Barley J, Jeffrey S, Carter N, Deanfield J. Angiotensin-converting enzyme genotype is not associated with endothelial dysfunction in subjects without other coronary risk factors. Atherosclerosis 1994;111:121-6.
34. van Geel PP, Voors AA, Oosterga M, et al. The angiotensin converting enzyme DD genotype is associated with a decreased response to angiotensin II in human arteries (abstr). J Am Coll Cardiol 1998;31:350A.
35. Ueda S, Meredith PA, Morton JJ, Connell JM, Elliott HL. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (Enalaprilat) in humans. Circulation 1998;98:2148-53.
36. Farhy RD, Carretero OA, Ho K-L, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993;72:1202-10.
37. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of Superoxide in angiotensin II-mediated but not catecholamine-induced hypertension. Circulation 1997;95:588-93.
38. Rajagopalan S, Harrison DG. Reversing endothelial dysfunction with ACE inhibitors. Circulation 1996;94:240-3.
39. Frielingsdorf J, Seiler C, Kaufmann P, Vassalli G, Suter T, Hess OM. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation 1996;93:1380-7.
40. Chen L, Haught H, Yang B, Saldeen TCP, Parathasarathy S, Mehta JL. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiathersoclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997;30:569-75.
41. Zhang X, Xie Y-W, Nasjletti A, Xu X, Wolin MS, Hintze TH. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation 1997;95:176-82.
42. Iwatsubo H, Nagano M, Sakai T, et al. Converting enzyme inhibitor improves forearm reactive hyperemia is essential hypertension. Hypertension 1997;29:286-90.
43. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-41.